SCHEMBL4297601

SCHEMBL4297601

COc1cc(Br)c(C)c(Br)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.56
CYP3A4 P08684 3/20 0.52
CYP1A1 P04798 4/20 0.42
CYP1B1 Q16678 4/20 0.42
CA2 P00918 3/20 0.40
CA1 P00915 2/20 0.40
CA12 O43570 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CRHR1 P34998 2/20 0.40
ACHE P22303 2/20 0.39
CA4 P22748 1/20 0.39
CYP1A2 P05177 2/20 0.37
CYP2E1 P05181 2/20 0.37
CYP2C8 P10632 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2A6 P11509 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP4B1 P13584 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30550473 0.87 ALDH1A1 (0.48) ALDH1A1CYP3A4CYP1A1CYP1B1CA2
SCHEMBL4694851 0.85 CRHR1 (0.46) ALDH1A1CYP3A4CYP1A1CYP1B1CA2
SCHEMBL19709408 0.83 ALDH1A1 (0.43) ALDH1A1CYP3A4CYP1A1CYP1B1CA2
SCHEMBL957652 0.79 CYP3A4 (0.40) ALDH1A1CYP3A4CRHR1CYP1A2
SCHEMBL11403757 0.79 ALDH1A1 (0.59) ALDH1A1CYP3A4CYP1A1CYP1B1CA2
SCHEMBL1119927 0.77 CA2 (0.56) ALDH1A1CYP3A4CYP1A1CYP1B1CA2
SCHEMBL7827443 0.76 LCK (0.52) ALDH1A1CYP3A4POLBL3MBTL1NPC1
SCHEMBL31125235 0.76 LCK (0.52) ALDH1A1CYP3A4POLBL3MBTL1NPC1
SCHEMBL9173991 0.74 ALDH1A1 (0.53) ALDH1A1CYP3A4CYP1A1CYP1B1CA2
SCHEMBL701066 0.74 ALDH1A1 (0.53) ALDH1A1CYP3A4CYP1A1CYP1B1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118852145-A GSPT1 degradation agent and application thereof 南京圣和药业股份有限公司 2024-10-29 CN disclosed
CN-117534545-A Compound for treating Alzheimer's disease based on artificial intelligence design, preparation method and medical application thereof 东北大学 2024-02-09 CN disclosed
EP-3504261-B1 FLAME-RETARDED POLYAMIDE COMPOSITION ICL IP AMERICA INC (US) 2023-08-02 EP disclosed
CN-116514771-A Carboxylic acid compound, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2023-08-01 CN disclosed
WO-2021224818-A1 ISOINDOLONE COMPOUNDS AS HPK1 INHIBITORS PFIZER INC. (US) 2021-11-11 WO disclosed
WO-2021224818-A1 ISOINDOLONE COMPOUNDS AS HPK1 INHIBITORS PFIZER INC. (US) 2021-11-11 WO disclosed
WO-2018044664-A1 FLAME-RETARDED POLYAMIDE COMPOSITION ICL-IP AMERICA INC. (US) 2018-03-08 WO disclosed
WO-2018026621-A1 FLAME-RETARDED POLYESTER COMPOSITION ICL-IP AMERICA INC. (US) 2018-02-08 WO disclosed
US-20160340498-A1 FLAME-RETARDED POLYOLEFIN POLYMER COMPOSITION WITH REDUCED ANTIMONY TRIOXIDE CONTENT ICL-IP AMERICA INC. (US) 2016-11-24 US disclosed
US-20160340498-A1 FLAME-RETARDED POLYOLEFIN POLYMER COMPOSITION WITH REDUCED ANTIMONY TRIOXIDE CONTENT ICL-IP AMERICA INC. (US) 2016-11-24 US disclosed
US-20060211727-A1 Novel compounds GLAXOSMITHKLINE LLC 2006-09-21 US disclosed
US-6809199-B2 ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES MERCK & CO., INC. 2004-10-26 US disclosed
EP-1345603-A4 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS MERCK & CO INC (US) 2004-09-08 EP disclosed
EP-1345603-A1 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS Merck & Co., Inc. (US) 2003-09-24 EP disclosed
WO-2002058695-A9 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS MERCK & CO INC (US) 2003-09-12 WO disclosed
US-20030092712-A1 (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents MERCK SHARP & DOHME CORP. 2003-05-15 US disclosed
US-20030032779-A1 Estrogen receptor ligands OHMAN LARS (SE) 2003-02-13 US disclosed
WO-2002058695-A1 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS MERCK & CO., INC. (US) 2002-08-01 WO disclosed
EP-0980386-A2 ESTROGEN RECEPTOR CRYSTALS AND LIGANDS KARO BIO AB (SE) 2000-02-23 EP disclosed
WO-1998056812-A2 ESTROGEN RECEPTOR CRYSTALS AND LIGANDS KARO BIO AB (SE) 1998-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092712-A1 (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents MAPK1, MAPK7, MAPKAPK2 ALDH1A1 867/4885CYP3A4 2923/4885CYP1A1 776/4885
US-20030032779-A1 Estrogen receptor ligands ESR1, ESRRB, GPER1 ALDH1A1 2183/4885CYP3A4 990/4885CYP1A1 965/4885
US-20060211727-A1 Novel compounds MAPKAPK2, CREBBP, MAPK1 ALDH1A1 3499/4885CYP3A4 2823/4885CYP1A1 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.